Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Conditions
NSCLC Stage IV · NSCLC, Stage III
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
CH Aix-en-Provence, Aix-en-Provence, Bouches Du Rhône, France
AP-HM, Marseille, Bouches Du Rhône, France
HIA Sainte Anne, Toulon, Var, France
CHU Angers, Angers, France
CHU Bordeaux, Bordeaux, France
CHU Brest, Brest, France
Centre François Baclesse, Caen, France
CH Chambéry, Chambéry, France
Hôpitaux civils de Colmar, Colmar, France
CHI Créteil, Créteil, France
CHD Vendée, La Roche-sur-Yon, France
CHRU Lille, Lille, France
CHU Limoges, Limoges, France
Contact: Study coordinator (Yannick SIMONNEAU, MD) · Yannick.simonneau@chu-limoges.fr · 05 55 05 55 55Hospices Civils de Lyon, Lyon, France
CH Cornouaille, Quimper, France
CHU Rennes, Rennes, France
CHU Rouen, Rouen, France
Hôpital Foch, Suresnes, France
CHU Toulouse, Toulouse, France
Hôpitaux Nord-Ouest, Villefranche-sur-Saône, France
Study leads
Olivier BYLICKI, MD, PhD, PR
Study Director
HIA Sainte Anne / Groupe Français d'Onco-Pneumologie
Laurent GREILLIER, MD, PhD, PR
Study Director
AP-HM / Groupe Français d'Onco-Pneumologie